Clinical trials
Small Cell Lung Carcinoma clinical trials
Below are recruiting small cell lung carcinoma clinical trials, each written for real people, not researchers. We’re tracking 747 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06364917RecruitingPhase 2
Comparing two immunotherapy options for PD-L1 negative lung cancer
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Birmingham, AlabamaAges 18–89 - NCT06394674RecruitingPhase 2
High-dose furmonertinib for lung cancer after osimertinib stops working
This trial tests a higher dose of a targeted therapy called furmonertinib for people with advanced lung cancer that has stopped responding to a previous drug called osimertinib. It may help if you have a certain EGFR mutation and your cancer has grown outside the brain.
ShanghaiAges 18–75 - NCT06437977RecruitingPhase 3
Pre-surgery treatment with radiation, immunotherapy, and chemo for stage II-III NSCLC
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
ShanghaiAges 18–75 - NCT06441773Recruiting
Lung rehab for advanced lung cancer on maintenance therapy
This study tests if a respiratory (breathing) rehabilitation program can improve quality of life for people with advanced non-small cell lung cancer who are on maintenance treatment after initial chemotherapy and immunotherapy.
BrestAges 18 years+ - NCT06445881RecruitingPhase 2
Herbal medicine for lung cancer before and after surgery
This trial is testing whether adding a traditional Chinese herbal formula (Modified Si Jun Zi Tang) to standard treatment before and after surgery can help people with early-stage non-small cell lung cancer. It aims to see if the herbs improve outcomes and reduce side effects.
Hangzhou, ZhejiangAges 18–75 - NCT06457906RecruitingPhase 3
Focused radiation vs whole brain radiation for up to 10 lung cancer brain spots
This trial compares two types of radiation for people with small cell lung cancer that has spread to the brain (10 or fewer spots). One approach uses focused radiation only on the tumors, the other treats the whole brain while trying to protect memory. The goal is to see which works better with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06479473RecruitingPhase 1/Phase 2
Radiation for leftover spots after chemo-immunotherapy in lung cancer
This trial is for people with extensive-stage small cell lung cancer. After standard chemo-immunotherapy, it tests whether giving radiation to all remaining tumor spots can improve outcomes.
Hefei, AnhuiAges 18–70 - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Sarasota, FloridaAges 18 years+ - NCT06496048RecruitingPhase 3
Testing lurbinectedin for small cell lung cancer that has returned
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Jilin CityAges 18 years+ - NCT06524427Recruiting
Robot vs. video-assisted lung cancer surgery study
This trial compares robot-assisted surgery to video-assisted surgery for removing lung cancer. It aims to see which approach works better for patients with early-stage non-small cell lung cancer.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT06554613RecruitingPhase 2
Olanzapine with first-line immunotherapy for advanced lung cancer trial
This trial tests whether adding the drug olanzapine to standard first-line immunotherapy (with or without chemotherapy) can help people with advanced lung cancer that does not have an EGFR mutation. It aims to improve treatment outcomes and quality of life.
Nanchang, JiangxiAges 18–75 - NCT06567015RecruitingPhase 1/Phase 2
STX-241 for advanced EGFR-mutant lung cancer after TKI failure
This trial tests an experimental drug called STX-241 for people with a specific type of advanced lung cancer (NSCLC) that has an EGFR mutation (exon 19 deletion or L858R) and has stopped responding to a third-generation EGFR inhibitor (like osimertinib). The drug aims to target a new mutation, C797X, that sometimes appears after osimertinib stops working.
Nashville, TennesseeAges 18 years+ - NCT06579196RecruitingPhase 1/Phase 2
Trabedersen with pembrolizumab for newly diagnosed advanced lung cancer
This trial tests a new drug, trabedersen, combined with the immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that hasn't been treated yet. It's for patients whose tumors have a protein called PD-L1 (at least 1%) and who are generally well enough to participate.
Omaha, NebraskaAges 19 years+ - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06620835RecruitingPhase 2
Optimizing local treatments for ALK-positive lung cancer on brigatinib
This trial is for people with advanced ALK-positive lung cancer who are already taking the targeted therapy brigatinib and have a few remaining spots of cancer. It tests whether adding local treatments (like surgery, focused radiation, or ablation) to the remaining spots can improve outcomes.
BrestAges 18 years+ - NCT06643000Recruiting
High-dose furmonertinib combo for EGFR lung cancer with brain lining spread
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
Zhengzhou, HenanAges 18 years+ - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06667167RecruitingPhase 2
First-line Keytruda + chemo then Keytruda + Trodelvy for SCLC
This trial tests a two-step treatment for extensive-stage small cell lung cancer: first, chemotherapy combined with Keytruda (an immunotherapy), followed by Keytruda plus Trodelvy (another targeted drug). The goal is to see if this combination helps people live longer and keeps the cancer under control.
Jerusalem, IsraelAges 18–99 - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT07177937RecruitingPhase 1
Study of DXC014 for advanced solid tumors
This trial tests DXC014, a new drug, in people with advanced solid tumors, including prostate cancer. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07518160RecruitingPhase 2
JS212 and JS111 for advanced lung cancer with EGFR mutations
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06732193Recruiting
Fissios App for recovery after lung cancer surgery
This trial tests whether using a smartphone app (Fissios) after lung cancer surgery helps you recover with fewer complications. If you are scheduled for lung surgery for non-small cell lung cancer and have a smartphone, you may be eligible.
Madrid, MadridAges 18 years+
Hear when a new Small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell lung carcinoma?
- Yes. Clin2 currently lists 747 recruiting small cell lung carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell lung carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell lung carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.